← All trials
NCT01918241
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2013
- Primary completion
- Jan 1, 2016
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Yangzhou No.1 People's HospitalCollaborator
- Changsha Central HospitalCollaborator
- Nanjing Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Peking UniversityCollaborator
- Inner Mongolia Medical UniversityCollaborator
- Shandong UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.